<DOC>
	<DOCNO>NCT02132689</DOCNO>
	<brief_summary>Currently clear guidance treatment moderate risk pulmonary embolism . The aim study compare two different therapeutic modality - standard anticoagulation versus thrombolytic treatment follow anticoagulation standard regimen state pulmonary embolism guideline .</brief_summary>
	<brief_title>Comparison Thrombgolytic Anticoagulation Therapy Submassive Pulmonary Embolism</brief_title>
	<detailed_description>Standard treatment moderate risk pulmonary embolism constitutes sole anticoagulation therapy . In case troponin positivity and/or echocardiographic finding i.e . thrombus RV thrombolytic therapy consider . The aim trial compare two treatment modality ability reduce/predict 12 month end-point : pulmonary hypertension , right ventricular failure , exercise capacity .</detailed_description>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Fibrinolytic Agents</mesh_term>
	<criteria>moderate risk pulmonary embolism define European Society Cardiology /ESC/ guideline sign informed consent patient willing sigh inform consent absolute contraindication thrombolysis inability obtain meaningfull echocardiographic imagesÂ¨ pulmonary arterial hypertension know right ventricular failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Moderate Risk Acute Pulmonary Embolism</keyword>
</DOC>